Advertisement
Advertisement
U.S. Markets open in 4 hrs 33 mins
Advertisement
Advertisement
Advertisement
Advertisement

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.0500-0.0200 (-1.87%)
At close: 04:00PM EDT
1.1100 +0.06 (+5.71%)
After hours: 06:45PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0700
Open1.0500
Bid0.9600 x 1000
Ask2.1800 x 1300
Day's Range1.0200 - 1.1300
52 Week Range0.9000 - 11.1800
Volume362,952
Avg. Volume419,004
Market Cap55.022M
Beta (5Y Monthly)1.79
PE Ratio (TTM)N/A
EPS (TTM)-2.2410
Earnings DateMar 16, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.38
  • American City Business Journals

    Raleigh drugmaker pursuing Covid treatment raising $15M to fund acquisitions

    Additionally, the company agreed to issue unregistered private warrants to the investor to purchase up to more than 13 million shares at $1.48 a share in a concurrent private placement, according to a filing with the U.S. Securities and Exchange Commission. RedHill's stock fell more than 30 percent Monday after the company disclosed the offering prior to markets opening. The offering follows the company signing a licensing deal with the South Korean corporation Kubo Co. Ltd for the exclusive rights to commercialize RedHill's investigational Covid-19 treatment called opaganib.

  • PR Newswire

    RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor

    RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement with a single leading healthcare investor for the purchase and sale of 10,563,380 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents), each ADS representing ten (10) ordinary shares, at a purchase price of $1.42 per ADS (or ADS equivalent), in a registered direct offering. RedHill has also agreed to issue

  • Insider Monkey

    Cathie Wood’s Latest Portfolio: 10 New Stock Picks in 2022

    In this article we will discuss some new stock picks of Cathie Wood’s hedge fund. You can skip this part and go directly to see the top 5 New Stock Picks of Cathie Wood in 2022. Despite huge criticism and losses, Cathie Wood’s hedge fund ARK Investment continues to attract investors amid promises of future […]

Advertisement
Advertisement